These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21083658)

  • 1. Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin.
    Petersen LC; Karpf DM; Agersø H; Hermit MB; Pelzer H; Persson E; Nichols TC; Ezban M
    Br J Haematol; 2011 Jan; 152(1):99-107. PubMed ID: 21083658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogs.
    Agersø H; Kristensen NR; Østergaard H; Karpf DM; Hermit MB; Pelzer H; Petersen LC; Ezban M
    Eur J Pharm Sci; 2011 Apr; 42(5):578-83. PubMed ID: 21382491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A.
    Sørensen B; Persson E; Ingerslev J
    Br J Haematol; 2007 Apr; 137(2):158-65. PubMed ID: 17391496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.
    Gray LD; Hussey MA; Larson BM; Machlus KR; Campbell RA; Koch G; Ezban M; Hedner U; Wolberg AS
    Thromb Res; 2011 Dec; 128(6):570-6. PubMed ID: 21561645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients.
    Brophy DF; Martin EJ; Nolte ME; Kuhn JG; Carr ME
    Haemophilia; 2007 Sep; 13(5):533-41. PubMed ID: 17880440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A.
    Brophy DF; Martin EJ; Nolte ME; Kuhn JG; Barrett JC; Ezban M
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):539-46. PubMed ID: 20581663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects.
    Møss J; Scharling B; Ezban M; Møller Sørensen T
    J Thromb Haemost; 2009 Feb; 7(2):299-305. PubMed ID: 19138379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of coagulant activity of factor VII and activated factor VII activity assays when used for determination of recombinant activated factor VII levels in plasma.
    Scharling B; Nielsen GG; Klitgaard T; Skovsted TA; Møss J; Segel S; Larsen LF
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):677-84. PubMed ID: 17890956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
    Aljamali MN; Kjalke M; Hedner U; Ezban M; Tranholm M
    Haemophilia; 2009 Nov; 15(6):1318-26. PubMed ID: 19659796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia.
    Allen GA; Persson E; Campbell RA; Ezban M; Hedner U; Wolberg AS
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):683-9. PubMed ID: 17204663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor VIII activation by factor VIIa analog (V158D/E296V/M298Q) in tissue factor-independent mechanisms.
    Ogiwara K; Nogami K; Shima M
    Thromb Haemost; 2011 Oct; 106(4):665-74. PubMed ID: 21901232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia.
    Agersø H; Tranholm M
    Haemophilia; 2012 Jul; 18 Suppl 5():6-10. PubMed ID: 22757678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice.
    Holmberg HL; Lauritzen B; Tranholm M; Ezban M
    J Thromb Haemost; 2009 Sep; 7(9):1517-22. PubMed ID: 19566792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. rFVIIa and NN1731 reduce bleeding in hydroxyethyl starch hemodiluted rabbits.
    Lauritzen B; Viuff D; Tranholm M; Ezban M
    J Trauma; 2010 Nov; 69(5):1196-202. PubMed ID: 20032791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma-derived factors VIIa and X mixtures (Byclot
    Ochi S; Takeyama M; Shima M; Nogami K
    Int J Hematol; 2020 Jun; 111(6):779-785. PubMed ID: 32030609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue.
    Larsen OH; Clausen N; Persson E; Ezban M; Ingerslev J; Sørensen B
    Br J Haematol; 2009 Jan; 144(1):99-106. PubMed ID: 19016728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.
    Sørensen B; Ingerslev J
    J Thromb Haemost; 2004 Jan; 2(1):102-10. PubMed ID: 14717973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation.
    Bysted BV; Scharling B; Møller T; Hansen BL
    Haemophilia; 2007 Sep; 13(5):527-32. PubMed ID: 17880439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog.
    Knudsen T; Kristensen AT; Nichols TC; Agersø H; Jensen AL; Kjalke M; Ezban M; Tranholm M
    Haemophilia; 2011 Nov; 17(6):962-70. PubMed ID: 21645178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.